Dr. Andreas A. Bastian
Chief Executive Officer (CEO), co-founder
Since 2008, Dr. A. A. Bastian is working on natural product-based antibiotics as lead compounds and co-invented in total three technologies for the selective modification of structurally complex natural products. Dr. Bastian studies Biomedical Chemistry at the University of Mainz in Germany and graduated with highest distinction in 2008. After his PhD studies (cum laude, 2012) at the University of Groningen, he received the Rubicon Research Grant from the Netherlands Organization for Research (NWO) to perform his postdoctoral studies at the University of Notre Dame in the United States. In 2015, he was awarded the prestigious Veni Grant from NWO and started his own research at the University of Groningen focusing in novel antibacterials for the treatment of life-threatening Gram-negative infections. In 2017, Dr. A. A. Bastian co-founded AGILeBiotics and is now full-time employed as managing director (CEO) leading the business and the development of novel antibiotics.
Dr. Maria Bastian
Chief Science Officer (CSO)
After finishing her studies in Biomedical Chemistry at the University of Mainz in Germany, Dr. Bastian started her PhD studies at the University of Groningen in 2009. Working in the group of Prof. Dr. Ben Feringa she gained experience in rout scouting and complex total synthesis of natural product inspired molecular structures. In 2014, she decided to perform her postdoctoral studies in the group of Prof. Dr. S. Mobashery at the University of Notre Dame in the United States. Dr. Bastian was involved in different stages of antibiotic development (in vitro and in vivo studies) and published her successful work in scientific journals. In 2016, Dr. Bastian moved back to the Netherlands, where she joined Syncom BV as Research Scientist before she joined AGILeBiotics as Chief Science Officer. At AGILeBiotics Dr. Bastian is taking the lead in various lead-optimization projects developing the next generation antibiotic against multidrug-resistant pathogens of major concern.
Dr. Bernard J. van Vliet
Chief Operating Officer (COO)
Dr. B. J. van Vliet is the CEO of Integrex Research B.V., a CRO in Groningen. During his career at Solvay Pharmaceuticals, Dr. Bernard van Vliet has managed a considerable number of drug discovery programs providing him with in depth experience in the various aspects of drug discovery. He has established a successful track record in the early development of Nurr-1/RXR agonists (SLV357, SLV359 and SLV360, up to pre-clinical candidates) for the modification of disease progression in Parkinson’s disease and Endothelin-1 converting enzyme inhibitors (SLV334, up to Phase IIa) for reduction of secondary damage in traumatic brain injury. At AGILeBiotics, Dr. B. van Vliet is acting Chief Operating Officer (COO) responsible for the preclinical screening and profiling activities according to pharma industry standards. He connects all partners of AGILeBiotics and reaches out for CROs essential for antibiotic development.
Reinier Schwietert, Ph.D.
Experienced Life Sciences Executive
Results-oriented life sciences executive with 25+ years of experience in the drug development sector. Former co-founder and co-owner of Xendo. Strong track record in building businesses up from scratch and developing and executing B2B sales and marketing strategies that generate demand, build brand awareness and drive revenue. Creative visionary with excellent communication skills. Passionate about science and taking on new business challenges and building effective and successful cross-functional teams in complex, innovative and knowledge-intensive business segments of the pharmaceutical/biotech/healthcare sectors.
Dr. M. Yagiz Unver
Dr. M. Yagiz Unver obtained his Master`s degree at Middle East Technical University, Ankara in 2013. After gaining experience in asymmetric synthesis and organocatalysis, he pursued his PhD in a medicinal chemistry group at University of Groningen under the supervisions of Prof. A. K. H. Hirsch and Prof. B. L. Feringa. Throughout his PhD, he has been working on several drug discovery projects in the early stage of drug development (hit-identification & optimization). Thereby, he employed novel methodologies with target-guided synthesis and structure/fragment-based drug design. Dr. Unver published his successful work in various scientific journals. During his PhD studies, he was also working at the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) in Saarbruecken (Germany), where he gained additional experience in drug development. After finishing his PhD in September 2017, he joined AGILeBiotics as a Research Scientist to support the development of novel antibiotic candidates against multidrug resistant infections.
Dr. Mina Raeisolsadati Oskouei
Dr. Mina Raeisolsadati Oskouei recieved her Master degree in organic chemistry at the University of Azarbaijan Shahid Madani (Iran) under the supervision of Dr. Adeleh Moshtaghi Zenouz. The results of her research about Dihydropyridine and dihydroquinolone derivatives have been published in various scientific journals. In 2012, she joined to molecular photonics group at the University of Amsterdam as a guest researcher. In 2014, she started her PhD studies under the supervision of Prof. A. M. Brouwer focusing on fluorogenic organocatalytic reactions. Her studies resulted in the synthesis of different chromene, dihydropyrimidine and BODIPY derivatives with potential application in medicinal chemistry and fluorescence imaging. In 2018, she joined to our R&D team focusing on the development of novel antibiotic candidates.
Dr. Francesco Lanza
After obtaining his bachelor degree in chemistry at the University of Messina (Italy) in 2010, Dr. Francesco Lanza moved to the University of Bologna (Italy), where he received his master degree (cum laude) for his work on the synthesis of oxindole derivatives using chiral thiourea catalysts. In September 2013, he joined the group of Prof. Dr. S. R. Harutyunyan at the Rijksuniversiteit Groningen as PhD candidate. During his PhD studies, Dr. Lanza worked on the development of new asymmetric catalytic processes to functionalise heterocyclic scaffolds, with particular accent on copper catalysed addition of organometallic reagent mediated by Lewis acid additives. His work has been published in high level scientific journals. In May 2018, Dr. Lanza joined our R&D team focusing on the synthesis of new antibiotic candidates.
Prof. Dr. Andreas Herrmann
Scientific Advisor, Co-founder
Prof. Herrmann holds the chair of Polymer Chemistry & Bioengineering at the Zernike Institute for Advanced Materials at the University of Groningen, is co-founder of AGILeBiotics and co-invented together with Prof. Adri Minnard and Dr. A. A. Bastian the OxaSelect technology. He has broad experience in establishing synthetic strategies for structurally complex drug candidates. Moreover, he is providing novel synthetic methods applicable for the lead-optimization process of our drug candidates. Additionally, Prof. Herrmann is supporting the development of AGILeBiotics’ drug pipeline by providing state-of-the-art laboratory facilities for testing antibiotic candidates in different bacterial strains.
Prof. Dr. Adriaan J. Minnaard
Prof. Dr. A. Minnaard is the Director of the Stratingh Institute for Chemistry and head of the Department of Chemical Biology at the University of Groningen. Prof. Minnaard co-invented and established our technology OxaSelect, and set the basis for the efficient drug development process we apply today at AGILeBiotics. As one of their main research topics, the Minnaard group embarked on the virtually unexplored field of selective catalytic modification of unprotected natural compounds, in the expectation that this will significantly contribute to the development of synthesis and chemical biology both. The challenge to selectively address various functionalities is in our opinion in the same ball park as that of selective C-H activation in natural products. Prof. Minnaard is supporting AGILeBiotics with the continuous optimization of our technology and development of novel methods for selective modification of natural product-based drugs. Further information on the work of the Minnaard group can be found at www.chemicalbiologygroningen.nl.